BA
INO icon

BlackRock Advisors’s Inovio Pharmaceuticals INO Stock Holding History

BlackRock Advisors’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$239K Sell
2,871
-65
-2% -$5.88K ﹤0.01% 2629
2016
Q3 		$328K Buy
2,936
+186
+7% +$20.6K ﹤0.01% 2401
2016
Q2 		$305K Sell
2,750
-21
-0.8% -$2.55K ﹤0.01% 2392
2016
Q1 		$290K Buy
2,771
+201
+8% +$15.5K ﹤0.01% 2364
2015
Q4 		$207K Sell
2,570
-1,217
-32% -$96.9K ﹤0.01% 2544
2015
Q3 		$263K Sell
3,787
-72
-2% -$6.27K ﹤0.01% 2572
2015
Q2 		$378K Buy
3,859
+710
+23% +$75.9K ﹤0.01% 2385
2015
Q1 		$308K Sell
3,149
-5,346
-63% -$518K ﹤0.01% 2425
2014
Q4 		$936K Sell
8,495
-534
-6% -$65.3K ﹤0.01% 1537
2014
Q3 		$1.07M Buy
9,029
+6,110
+209% +$761K ﹤0.01% 1394
2014
Q2 		$379K Buy
2,919
+2,204
+308% +$260K ﹤0.01% 2215
2014
Q1 		$114K Buy
715
+87
+14% +$12.5K ﹤0.01% 2974
2013
Q4 		$87K Buy
628
+48
+8% +$4.8K ﹤0.01% 3099
2013
Q3 		$58K Buy
580
+243
+72% +$20.4K ﹤0.01% 3147
2013
Q2 		$13K Buy
+337
New +$10.2K ﹤0.01% 3349

Other funds holding INO

BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

BlackRock Advisors's INO Position: Q4 2016 in Review

BlackRock Advisors reduced its Inovio Pharmaceuticals (INO) stake by 2.2% in Q4 2016, selling an estimated $5.88K and leaving 2,871 shares worth $239K. The position accounts for ﹤0.01% of the portfolio, ranked #2629.

BlackRock Advisors first reported a position in INO in Q2 2013 and has held it in 15 quarters since. The position peaked at $1.07M in Q3 2014. 125 funds tracked by Wall St. Rank hold INO as of Q4 2016.

  • BlackRock Advisors held 2,871 shares of Inovio Pharmaceuticals worth $239K as of Q4 2016.
  • BlackRock Advisors sold 65 Inovio Pharmaceuticals shares in Q4 2016, an estimated $5.88K.
  • Inovio Pharmaceuticals made up ﹤0.01% of BlackRock Advisors's portfolio in Q4 2016, its #2629 holding.
  • BlackRock Advisors first reported a position in Inovio Pharmaceuticals in Q2 2013 and has held it in 15 quarters since.
  • BlackRock Advisors's Inovio Pharmaceuticals position peaked at $1.07M in Q3 2014.
  • 125 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.